Pure Biologics Income Statement

Financials in millions PLN. Fiscal year is January - December.

Millions PLN. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	-	-	-	0.66	0.25	0.57
Revenue Growth (YoY)	-	-	-	160.63%	-55.59%	-67.79%
Cost of Revenue	0.03	0.05	0.06	6.07	4.28	4.51
Gross Profit	-0.03	-0.05	-0.06	-5.41	-4.03	-3.94
Selling, General & Admin	15.07	14.92	18.26	28.71	20.69	20.46
Other Operating Expenses	-4.09	-2.89	-10.99	-11.93	-17.15	-15.95
Operating Expenses	11.25	12.34	7.48	19.28	6.46	7.62
Operating Income	-11.28	-12.38	-7.54	-24.68	-10.49	-11.56
Interest Expense	-1.92	-1.33	-0.86	-0.33	-0.23	-0.35
Interest & Investment Income	-	-	0.28	0.2	0.09	0.03
Currency Exchange Gain (Loss)	0.52	0.52	-0.41	-0.02	-0.06	0.12
Other Non Operating Income (Expenses)	0	-	-0	-	-	-
EBT Excluding Unusual Items	-12.67	-13.19	-8.53	-24.83	-10.69	-11.76
Gain (Loss) on Sale of Investments	-	-	-0.02	-0.82	-1.09	-
Gain (Loss) on Sale of Assets	-	-	0.01	0.05	0.01	-
Other Unusual Items	-	-	-1.62	-	-	-
Pretax Income	-12.67	-13.19	-10.15	-25.6	-11.77	-11.76
Earnings From Continuing Operations	-12.67	-13.19	-10.15	-25.6	-11.77	-11.76
Earnings From Discontinued Operations	-5.26	-6.25	-25.55	-	-	-
Net Income	-17.93	-19.44	-35.69	-25.6	-11.77	-11.76
Net Income to Common	-17.93	-19.44	-35.69	-25.6	-11.77	-11.76
Shares Outstanding (Basic)	4	3	3	2	2	2
Shares Outstanding (Diluted)	4	3	3	2	2	2
Shares Change (YoY)	18.06%	9.27%	41.50%	1.48%	34.29%	8.48%
EPS (Basic)	-4.52	-5.58	-11.19	-11.36	-5.30	-7.11
EPS (Diluted)	-4.52	-5.58	-11.19	-11.36	-5.30	-7.11
Free Cash Flow	-5.12	-10.83	-23.44	-23.15	-24.71	-1.91
Free Cash Flow Per Share	-1.29	-3.11	-7.35	-10.27	-11.12	-1.16
Operating Margin	-	-	-	-3728.40%	-4129.13%	-2020.10%
Profit Margin	-	-	-	-3867.52%	-4631.89%	-2055.24%
Free Cash Flow Margin	-	-	-	-3496.22%	-9727.56%	-334.62%
EBITDA	-11.14	-12.24	-7.47	-22.46	-7.84	-8.66
D&A For EBITDA	0.14	0.14	0.07	2.23	2.65	2.9
EBIT	-11.28	-12.38	-7.54	-24.68	-10.49	-11.56

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.